View
214
Download
0
Category
Preview:
Citation preview
8/14/2019 Menopause After Breast Cancer
1/14
Menopause after breastMenopause after breastcancercancer
RMORMO
Gordon DingGordon Ding
8/14/2019 Menopause After Breast Cancer
2/14
1. Predictors of menopause after breast cancer1. Predictors of menopause after breast cancer
2. Return of ovarian function after adjuvant2. Return of ovarian function after adjuvant
chemotherapy use of aromatase inhibitorchemotherapy use of aromatase inhibitor
8/14/2019 Menopause After Breast Cancer
3/14
BackgroundBackground
25% Breast Ca premenopausal25% Breast Ca premenopausal 1,21,2
+ use of adjuvant chemotherapy+ use of adjuvant chemotherapy
Long term consequence:Long term consequence: Premature menopausePremature menopause
+ prolonged exposure to risks of menopause+ prolonged exposure to risks of menopause
8/14/2019 Menopause After Breast Cancer
4/14
Predicting chemotherapy-inducedPredicting chemotherapy-induced
menopausemenopause Age at diagnosisAge at diagnosis Use of adjuvant systemic treatmentUse of adjuvant systemic treatment
Change in BMIChange in BMI
Blood markersBlood markers 33 Measuring estradiol, LH, FSH, inhibin only reflectsMeasuring estradiol, LH, FSH, inhibin only reflects
function at that point of timefunction at that point of time Unable to predict the return of ovarian functionUnable to predict the return of ovarian function best marker for return of ovarian fn is menstruationbest marker for return of ovarian fn is menstruation Serial monitoring may assist in pt selection for AISerial monitoring may assist in pt selection for AI
8/14/2019 Menopause After Breast Cancer
5/14
Useful PredictorsUseful Predictors
AGEAGE 1,21,2
76-9722-61Risk
%
>40< 40Age
8/14/2019 Menopause After Breast Cancer
6/14
8/14/2019 Menopause After Breast Cancer
7/14
Risk of menopause during first yearRisk of menopause during first year
after breast cancer diagnosisafter breast cancer diagnosis 22
183 premenopausal women183 premenopausal women T1-3 N0-1 M0, primary surgical resection w AxT1-3 N0-1 M0, primary surgical resection w Ax
dissectiondissection Chemotherapy or chemotherapy+tamoxifen orChemotherapy or chemotherapy+tamoxifen or
taxmoxifen alone or no treatment.taxmoxifen alone or no treatment.
Defn -- MenopauseDefn -- Menopause
Data collected: age, BMI, tumour stage, receptorData collected: age, BMI, tumour stage, receptorstatus, radiation treatment, adjuvant treatmentstatus, radiation treatment, adjuvant treatmentand duration of treatment + age at onset ofand duration of treatment + age at onset ofmenopausemenopause
2.Goodwin, PJ et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol
17;8; 1999
8/14/2019 Menopause After Breast Cancer
8/14
Risk of menopause during first yearRisk of menopause during first year
after breast cancer diagnosisafter breast cancer diagnosis
Final multivariate modelFinal multivariate model
0.034Tamoxifen
< 0.00001Chemotherapy
< 0.00001Age
PVariable
8/14/2019 Menopause After Breast Cancer
9/14
8/14/2019 Menopause After Breast Cancer
10/14
Return of Ovarian functionReturn of Ovarian function
Up to 11% of woman spontaneously recoversUp to 11% of woman spontaneously recovers
(higher in younger women)(higher in younger women) 66
One study showed 27% recovery w the use ofOne study showed 27% recovery w the use of
AIAIConcerns:Concerns:
1. Anticancer efficacy reduced1. Anticancer efficacy reduced
2. Risk of unwanted pregnancy2. Risk of unwanted pregnancy
Managing of this group of patients maybeManaging of this group of patients maybe
challengingchallenging
8/14/2019 Menopause After Breast Cancer
11/14
? Suggested guideline for AI for early? Suggested guideline for AI for early
breast cancer after CIAbreast cancer after CIA
Baseline evaluationsBaseline evaluations 33
4 week prior to chemo4 week prior to chemo Estradiol, FSH/LHEstradiol, FSH/LH
Ca, DEXACa, DEXA
8/14/2019 Menopause After Breast Cancer
12/14
-- w/i pre-menopausal range (N
FSH/LH, estradiol > 20),
Tamoxifen alone, or
Ovarian ablation w tamoxifen; or
Ovarian ablation w AI or
Refer forSOFT trial 5,6
Serial
estradiol,
LH/ FSH
> 40
-- post-menopause, (high FSH/LH,
estradiol < 10),
AI is appropriate; serial monitoring
every 6/12
Serial
estadiol,
LH/FSH
> 40
If estrogen depletion desired, ovariansuppression with AIN/A< 40
RecommendationBlood testsAge
8/14/2019 Menopause After Breast Cancer
13/14
Suppression of Ovarian Function TrialSuppression of Ovarian Function Trial77
Phase III StudyPhase III Study
Evaluates the role of ovarian suppression andEvaluates the role of ovarian suppression and
the role of exemestane (AI) as adjuvant therapythe role of exemestane (AI) as adjuvant therapy
for premenopausal women with endocrinefor premenopausal women with endocrineresponsive breast cancerresponsive breast cancer
OS + tamoxifenOS + tamoxifen vv tamoxifentamoxifen OS + exemestaneOS + exemestane vv tamoxifentamoxifen
OS + exemestaneOS + exemestane vv OS + tamoxifenOS + tamoxifen
8/14/2019 Menopause After Breast Cancer
14/14
ReferencesReferences
1. Knobf M. The influence of endocrine effects of adjuvant therapy on quality of life
outcomes in younger breast cancer survivors. Oncologist 11;96-110 2006
2.Goodwin, PJ et al. Risk of menopause during the first year after breast cancer diagnosis.
J Clin Oncol 17;8;2365-70 1999
3.Ganz PA and Greendale GA. Menopause and breast cancer: addressing the secondary
health effects of adjuvant chemotherapy J Clin Oncol 19;14;3303-05 20014. Welt CK, Shapiro C. Ovarian failure due to anticancer drugs and radiation. UpToDate
5. Krop IE and Winer EP. Ovarian suppression for breast cancer: An effective treatment in
search of a home. J Clin Oncol 23;25;5869-72 2005
6. Smith IE, Dowsett M et al. Adjuvant Aromatase inhibitors for early breast cancer after
chemotherapy induced amenorrhoea: caution and suggested guidelines. J Clin Oncol
24;16; 20067. Australian New Zealand Cancer Trials Group. http://www.anzbctg.org/
Recommended